(Q40744556)

English

Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group

scientific article published on October 2000

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

23 September 2017

Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group (English)

1 reference

Europe PubMed Central

23 September 2017

author name string

Kaplan S

1

1 reference

Europe PubMed Central

23 September 2017

Garvin D

2

1 reference

Europe PubMed Central

23 September 2017

Gilhooly P

3

1 reference

Europe PubMed Central

23 September 2017

Koppel M

4

1 reference

Europe PubMed Central

23 September 2017

Labasky R

5

1 reference

Europe PubMed Central

23 September 2017

Milsten R

6

1 reference

Europe PubMed Central

23 September 2017

Reddy P

7

1 reference

Europe PubMed Central

23 September 2017

Rosenberg S

8

1 reference

Europe PubMed Central

23 September 2017

Sussman D

9

1 reference

Europe PubMed Central

23 September 2017

White C

10

1 reference

Europe PubMed Central

23 September 2017

Lee M

11

1 reference

Europe PubMed Central

23 September 2017

Pappas F

12

1 reference

Europe PubMed Central

23 September 2017

Waldstreicher J

13

1 reference

Europe PubMed Central

23 September 2017

language of work or name

0 references

publication date

1 October 2000

1 reference

Europe PubMed Central

23 September 2017

1 reference

Europe PubMed Central

23 September 2017

56

1 reference

Europe PubMed Central

23 September 2017

610-616

1 reference

Europe PubMed Central

23 September 2017

4

1 reference

Europe PubMed Central

23 September 2017

The development of human benign prostatic hyperplasia with age

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900724-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The prevalence of prostatism: a population-based survey of urinary symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900724-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Health-related quality of life associated with lower urinary tract symptoms in four countries.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900724-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Health status and quality of life of British men with lower urinary tract symptoms: results from the SF-36.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900724-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Natural history of prostatism: impaired health states in men with lower urinary tract symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900724-X

7 January 2021

based on heuristic

inferred from DOI database lookup

International comparison of the community prevalence of symptoms of prostatism in four countries.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900724-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900724-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Natural history of prostatism: risk factors for acute urinary retention

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900724-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900724-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900724-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900724-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900724-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900724-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900724-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Stud

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900724-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900724-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of a symptoms questionnaire for benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900724-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900724-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900724-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900724-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of doxazosin in patients with mild, intermediate, and severe benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900724-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The so-called "placebo effect" in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900724-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900724-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900724-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate specific antigen in a community-based sample of men without prostate cancer: correlations with prostate volume, age, body mass index, and symptoms of prostatism.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900724-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900724-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0090-4295(00)00724-X

1 reference

Europe PubMed Central

23 September 2017

1 reference

Europe PubMed Central

23 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40744556&oldid=1906337208"